Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New anticoagulant strategies

J Weitz1, J Hirsh

  • 1Department of Medicine, McMaster University.

The Journal of Laboratory and Clinical Medicine
|October 1, 1993
PubMed
Summary
This summary is machine-generated.

New antithrombotic agents like low molecular weight heparin (LMWH) offer improved options for preventing and treating venous thromboembolic disease. Direct thrombin and GPIIb-IIIa inhibitors show promise for arterial thrombosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conserved and sexually dimorphic behavioral responses to biogenic amines in decapitated Drosophila.

Proceedings of the National Academy of Sciences of the United States of America·1997
Same author

Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy.

Annals of internal medicine·1997
Same author

Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.

Circulation·1997
Same author

Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study.

Circulation·1996
Same author

Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis.

Haemostasis·1996
Same author

Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo.

Blood·1996
Same journal

Studies on streptomycin; assay in body fluids.

The Journal of laboratory and clinical medicine·2010
Same journal

Gastrocolic fistula; an experimental study.

The Journal of laboratory and clinical medicine·2010
Same journal

An isolated heart perfusion system adapted to the determination of nongaseous metabolities; with sample data upon the isolated monkey heart.

The Journal of laboratory and clinical medicine·2010
Same journal

A new type of glass cage for metabolism studies.

The Journal of laboratory and clinical medicine·2010
Same journal

A simple electrocardiograph contact electrode for use with the smaller laboratory animal.

The Journal of laboratory and clinical medicine·2010
Same journal

A primary standard for the colorimetric determination of hemoglobin.

The Journal of laboratory and clinical medicine·2010
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Hematology

Background:

  • Standard heparin has limitations, driving the development of novel antithrombotic agents.
  • Low molecular weight heparin (LMWH) preparations are now approved and widely used.
  • Direct thrombin inhibitors and GPIIb-IIIa inhibitors are also in advanced clinical evaluation.

Purpose of the Study:

  • To review the clinical utility and potential of newer antithrombotic agents.
  • To evaluate the efficacy of LMWH in venous thromboembolic disease.
  • To assess the role of novel agents in arterial thrombosis.

Main Methods:

  • Review of existing clinical data and ongoing evaluations of antithrombotic agents.
  • Analysis of LMWH's effectiveness in venous thromboembolism prevention and treatment.

Related Experiment Videos

  • Assessment of direct thrombin inhibitors and GPIIb-IIIa inhibitors in arterial thrombosis.

    • Main Results:

    • LMWH is effective in preventing venous thromboembolic disease and shows a predictable dose response for treatment.
    • Further research is needed to compare LMWH with standard heparin in coronary interventions.
    • Hirudin, hirulog, and 7E3 demonstrate significant promise for treating arterial thrombosis.

    Conclusions:

    • Novel antithrombotic agents, including LMWH, direct thrombin inhibitors, and GPIIb-IIIa inhibitors, represent significant advancements.
    • LMWH is a valuable option for venous thromboembolic disease management.
    • Emerging agents like hirudin, hirulog, and 7E3 are expected to become important in arterial thrombosis treatment.